BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

...I-SPY Adaptive Trial” ). I-SPY COVID is evaluating razuprotafib from Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO), AbbVie’s cenicriviroc...
...narrower focus than dexamethasone, a broad immunosuppressant, and target different biological mechanisms associated with ARDS. Cenicriviroc...
...type B Tie2 - Tyrosine kinase receptor 2 Sandi Wong, Assistant Editor Razuprotafib (AKB-9778) Otezla, apremilast (CC-10004) cenicriviroc (tbr-652, TAK-652) Firazyr...
BioCentury | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

...molecules. Data from two Phase II trials of tropifexor monotherapy and a combination study with cenicriviroc...
BioCentury | Apr 12, 2019
Company News

Gilead, Novo team up to combine NASH compounds

...Novartis also has a NASH deal with Allergan plc (NYSE:AGN) to evaluate tropifexor plus Allergan's cenicriviroc...
...NR1H4) - Farnesoid X receptor; GLP-1R (GLP1R) - Glucagon-like peptide-1 receptor Mary Romeo, Staff Writer cenicriviroc (tbr-652, TAK-652) GS-0976...
BioCentury | Feb 23, 2019
Product Development

Benchmarks for NASH

...worsening of NASH Complete enrollment 2019 Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) / Allergan plc (NYSE:AGN) Cenicriviroc...
...Pharmaceuticals Inc. (NASDAQ:ICPT), New York, N.Y. University Hospital Aachen, Aachen, Germany Allison Johnson, Staff Writer cenicriviroc (tbr-652, TAK-652) elafibranor...
BioCentury | Dec 5, 2018
Politics & Policy

FDA NASH guidance charts course for surrogate endpoints tied to biopsies

...are Ocaliva obeticholic acid from Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), selonsertib from Gilead Sciences Inc. (NASDAQ:GILD), cenicriviroc...
...treat primary biliary cirrhosis (PBC); selonsertib is an apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor; cenicriviroc...
...measures (see "New Endpoints in NASH" ). Comments are due Feb. 4, 2019. Emily Cukier cenicriviroc (tbr-652, TAK-652) elafibranor...
BioCentury | Nov 19, 2018
Financial News

NASH company Genfit planning U.S. listing

...an inhibitor of apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) from Gilead Sciences Inc. (NASDAQ:GILD); and cenicriviroc...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...therapy corrected this increase 732 Novartis AG (NYSE:NVS; SIX:NOVN) / Allergan plc (NYSE:AGN) Tropifexor + cenicriviroc...
...PBC), Gilead Sciences Inc.’s selonsertib, an apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor; Allergan plc’s cenicriviroc...
...Viking Therapeutics Inc. (NASDAQ:VKTX), San Diego, Calif. Emily Cukier, Senior Writer Aramchol (arachidyl amino cholanoic acid) cenicriviroc (tbr-652, TAK-652) elafibranor...
BioCentury | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...liver fibrosis. Last year, Novartis partnered with Allergan plc (NYSE:AGN) to evaluate tropifexor plus Allergan's cenicriviroc...
...is in the Phase II TANDEM trial to treat NASH and liver fibrosis. Allergan acquired cenicriviroc...
BioCentury | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

...liver fibrosis. Last year, Novartis partnered with Allergan plc (NYSE:AGN) to evaluate tropifexor plus Allergan's cenicriviroc...
...is in the Phase II TANDEM trial to treat NASH and liver fibrosis. Allergan acquired cenicriviroc...
BioCentury | Mar 16, 2018
Emerging Company Profile

Cirius safety

...the clinic, including four in Phase III: Ocaliva obeticholic acid from Intercept Pharmaceuticals Inc., cenicriviroc (TAK-652...
Items per page:
1 - 10 of 58